Ascentage Pharma Group International (HKG:6855)
Hong Kong · Delayed Price · Currency is HKD 52.35
-1.00 (-1.87%)
Apr 17, 2026, 1:04 PM HKT
Ascentage Pharma Group International Employees
Ascentage Pharma Group International had 767 employees as of December 31, 2025. The number of employees increased by 200 or 35.27% compared to the previous year.
Employees
767
Change
200
Growth
35.27%
Revenue / Employee
832.97K HKD
Profits / Employee
-1.80M HKD
Market Cap
19.64B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 767 | 200 | 35.27% |
| Jun 30, 2025 | 605 | - | - |
| Dec 31, 2024 | 567 | -16 | -2.74% |
| Dec 31, 2023 | 583 | 3 | 0.52% |
| Dec 31, 2022 | 580 | -33 | -5.38% |
| Dec 31, 2021 | 613 | 180 | 41.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,165 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,625 |
| Everest Medicines | 722 |
| HBM Holdings | 272 |
| Duality Biotherapeutics | 231 |
| Ascletis Pharma | 208 |
| CStone Pharmaceuticals | 136 |
Ascentage Pharma Group International News
- 20 days ago - Full Year 2025 Ascentage Pharma Group International Earnings Presentation Transcript - GuruFocus
- 22 days ago - Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 - GlobeNewsWire
- 6 weeks ago - Ascentage Pharma Group International is Now Oversold (AAPG) - Nasdaq
- 2 months ago - Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewsWire
- 3 months ago - Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Benzinga